Botanix Pharmaceuticals Limited (BXPHF)
| Market Cap | 561.84M |
| Revenue (ttm) | 1.28M |
| Net Income (ttm) | -24.32M |
| Shares Out | n/a |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,000 |
| Average Volume | 2,475 |
| Open | 0.2300 |
| Previous Close | 0.2300 |
| Day's Range | 0.2300 - 0.2300 |
| 52-Week Range | 0.0085 - 0.5000 |
| Beta | 1.27 |
| RSI | 42.41 |
| Earnings Date | May 26, 2025 |
About Botanix Pharmaceuticals
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia and the United States. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIa clinical trials for the treatment of staphyloc... [Read more]
Financial Performance
In 2024, Botanix Pharmaceuticals's revenue was 2.07 million, a decrease of -45.14% compared to the previous year's 3.77 million. Losses were -13.87 million, 51.5% more than in 2023.
Financial numbers in AUD Financial StatementsNews
Botanix Pharmaceuticals taps investors for $40m; Euroz, E&P in tow
The ASX-listed company had Euroz Hartleys and E&P Capital offering shares at 33¢ each.
This media company’s share price is tipped to double
Lennox small caps manager Liam Donohue says he’s bullish on Botanix Pharmaceuticals and explains why he is eyeing up some former market darlings.